Opioid-Induced Constipation Industry Research Report 2024

Opioid-Induced Constipation Industry Research Report 2024


Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Highlights

The global Opioid-Induced Constipation market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid-Induced Constipation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid-Induced Constipation.
The Opioid-Induced Constipation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid-Induced Constipation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi

Product Type Insights

Global markets are presented by Opioid-Induced Constipation type, along with growth forecasts through 2030. Estimates on sales and revenue are based on the price in the supply chain at which the Opioid-Induced Constipation are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Opioid-Induced Constipation segment by Type

Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Opioid-Induced Constipation market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Opioid-Induced Constipation market.
Opioid-Induced Constipation segment by Application
Hospital
Pharmacy
Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Opioid-Induced Constipation market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Opioid-Induced Constipation industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Opioid-Induced Constipation by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Opioid-Induced Constipation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Opioid-Induced Constipation Market Size (2019-2030) & (US$ Million)
2.2.2 Global Opioid-Induced Constipation Sales (2019-2030)
2.2.3 Global Opioid-Induced Constipation Market Average Price (2019-2030)
2.3 Opioid-Induced Constipation by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
2.4 Opioid-Induced Constipation by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Hospital
2.4.3 Pharmacy
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Opioid-Induced Constipation Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Opioid-Induced Constipation Revenue of Manufacturers (2019-2024)
3.4 Global Opioid-Induced Constipation Average Price by Manufacturers (2019-2024)
3.5 Global Opioid-Induced Constipation Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Opioid-Induced Constipation, Product Type & Application
3.8 Global Manufacturers of Opioid-Induced Constipation, Date of Enter into This Industry
3.9 Global Opioid-Induced Constipation Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Takeda Pharmaceuticals
4.1.1 Takeda Pharmaceuticals Company Information
4.1.2 Takeda Pharmaceuticals Business Overview
4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
4.1.5 Takeda Pharmaceuticals Recent Developments
4.2 Bayer
4.2.1 Bayer Company Information
4.2.2 Bayer Business Overview
4.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Bayer Opioid-Induced Constipation Product Portfolio
4.2.5 Bayer Recent Developments
4.3 Sanofi
4.3.1 Sanofi Company Information
4.3.2 Sanofi Business Overview
4.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
4.3.5 Sanofi Recent Developments
4.4 Mallinckrodt
4.4.1 Mallinckrodt Company Information
4.4.2 Mallinckrodt Business Overview
4.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
4.4.5 Mallinckrodt Recent Developments
4.5 Salix (Bausch Health)
4.5.1 Salix (Bausch Health) Company Information
4.5.2 Salix (Bausch Health) Business Overview
4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
4.5.5 Salix (Bausch Health) Recent Developments
4.6 AstraZeneca
4.6.1 AstraZeneca Company Information
4.6.2 AstraZeneca Business Overview
4.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
4.6.5 AstraZeneca Recent Developments
4.7 Progenics Pharmaceuticals
4.7.1 Progenics Pharmaceuticals Company Information
4.7.2 Progenics Pharmaceuticals Business Overview
4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
4.7.5 Progenics Pharmaceuticals Recent Developments
4.8 Purdue Pharm
4.8.1 Purdue Pharm Company Information
4.8.2 Purdue Pharm Business Overview
4.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
4.8.5 Purdue Pharm Recent Developments
4.9 Nektar Therapeutics
4.9.1 Nektar Therapeutics Company Information
4.9.2 Nektar Therapeutics Business Overview
4.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
4.9.5 Nektar Therapeutics Recent Developments
4.10 Daiichi Sankyo
4.10.1 Daiichi Sankyo Company Information
4.10.2 Daiichi Sankyo Business Overview
4.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
4.10.5 Daiichi Sankyo Recent Developments
6.11 Prestige
6.11.1 Prestige Company Information
6.11.2 Prestige Opioid-Induced Constipation Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments
6.12 GSK
6.12.1 GSK Company Information
6.12.2 GSK Opioid-Induced Constipation Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments
6.13 Shionogi
6.13.1 Shionogi Company Information
6.13.2 Shionogi Opioid-Induced Constipation Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments
5 Global Opioid-Induced Constipation Market Scenario by Region
5.1 Global Opioid-Induced Constipation Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Opioid-Induced Constipation Sales by Region: 2019-2030
5.2.1 Global Opioid-Induced Constipation Sales by Region: 2019-2024
5.2.2 Global Opioid-Induced Constipation Sales by Region: 2025-2030
5.3 Global Opioid-Induced Constipation Revenue by Region: 2019-2030
5.3.1 Global Opioid-Induced Constipation Revenue by Region: 2019-2024
5.3.2 Global Opioid-Induced Constipation Revenue by Region: 2025-2030
5.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
5.4.1 North America Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Opioid-Induced Constipation Sales by Country (2019-2030)
5.4.3 North America Opioid-Induced Constipation Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
5.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Opioid-Induced Constipation Sales by Country (2019-2030)
5.5.3 Europe Opioid-Induced Constipation Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Country
5.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Opioid-Induced Constipation Sales by Country (2019-2030)
5.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
5.7.1 Latin America Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Opioid-Induced Constipation Sales by Country (2019-2030)
5.7.3 Latin America Opioid-Induced Constipation Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
5.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2019-2030)
5.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Opioid-Induced Constipation Sales by Type (2019-2030)
6.1.1 Global Opioid-Induced Constipation Sales by Type (2019-2030) & (K Units)
6.1.2 Global Opioid-Induced Constipation Sales Market Share by Type (2019-2030)
6.2 Global Opioid-Induced Constipation Revenue by Type (2019-2030)
6.2.1 Global Opioid-Induced Constipation Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2019-2030)
6.3 Global Opioid-Induced Constipation Price by Type (2019-2030)
7 Segment by Application
7.1 Global Opioid-Induced Constipation Sales by Application (2019-2030)
7.1.1 Global Opioid-Induced Constipation Sales by Application (2019-2030) & (K Units)
7.1.2 Global Opioid-Induced Constipation Sales Market Share by Application (2019-2030)
7.2 Global Opioid-Induced Constipation Revenue by Application (2019-2030)
6.2.1 Global Opioid-Induced Constipation Sales by Application (2019-2030) & (US$ Million)
6.2.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2019-2030)
7.3 Global Opioid-Induced Constipation Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Opioid-Induced Constipation Value Chain Analysis
8.1.1 Opioid-Induced Constipation Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Opioid-Induced Constipation Production Mode & Process
8.2 Opioid-Induced Constipation Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Opioid-Induced Constipation Distributors
8.2.3 Opioid-Induced Constipation Customers
9 Global Opioid-Induced Constipation Analyzing Market Dynamics
9.1 Opioid-Induced Constipation Industry Trends
9.2 Opioid-Induced Constipation Industry Drivers
9.3 Opioid-Induced Constipation Industry Opportunities and Challenges
9.4 Opioid-Induced Constipation Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 5. Global Opioid-Induced Constipation Volume and Revenue Market Size and CAGR of Manufacturers (2019 Versus 2023)
Table 6. Global Opioid-Induced Constipation Sales (K Units) of Manufacturers (2019-2024)
Table 7. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2019-2024)
Table 8. Global Opioid-Induced Constipation Revenue of Manufacturers (2019-2024)
Table 9. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2019-2024)
Table 10. Global Market Opioid-Induced Constipation Average Price (USD/Unit) of Manufacturers (2019-2024)
Table 11. Global Opioid-Induced Constipation Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Manufacturers of Opioid-Induced Constipation, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Opioid-Induced Constipation by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Takeda Pharmaceuticals Company Information
Table 17. Takeda Pharmaceuticals Business Overview
Table 18. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 19. Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
Table 20. Takeda Pharmaceuticals Recent Developments
Table 21. Bayer Company Information
Table 22. Bayer Business Overview
Table 23. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 24. Bayer Opioid-Induced Constipation Product Portfolio
Table 25. Bayer Recent Developments
Table 26. Sanofi Company Information
Table 27. Sanofi Business Overview
Table 28. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 29. Sanofi Opioid-Induced Constipation Product Portfolio
Table 30. Sanofi Recent Developments
Table 31. Mallinckrodt Company Information
Table 32. Mallinckrodt Business Overview
Table 33. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 34. Mallinckrodt Opioid-Induced Constipation Product Portfolio
Table 35. Mallinckrodt Recent Developments
Table 36. Salix (Bausch Health) Company Information
Table 37. Salix (Bausch Health) Business Overview
Table 38. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 39. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
Table 40. Salix (Bausch Health) Recent Developments
Table 41. AstraZeneca Company Information
Table 42. AstraZeneca Business Overview
Table 43. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 44. AstraZeneca Opioid-Induced Constipation Product Portfolio
Table 45. AstraZeneca Recent Developments
Table 46. Progenics Pharmaceuticals Company Information
Table 47. Progenics Pharmaceuticals Business Overview
Table 48. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
Table 50. Progenics Pharmaceuticals Recent Developments
Table 51. Purdue Pharm Company Information
Table 52. Purdue Pharm Business Overview
Table 53. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 54. Purdue Pharm Opioid-Induced Constipation Product Portfolio
Table 55. Purdue Pharm Recent Developments
Table 56. Nektar Therapeutics Company Information
Table 57. Nektar Therapeutics Business Overview
Table 58. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 59. Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
Table 60. Nektar Therapeutics Recent Developments
Table 61. Daiichi Sankyo Company Information
Table 62. Daiichi Sankyo Business Overview
Table 63. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
Table 65. Daiichi Sankyo Recent Developments
Table 66. Prestige Company Information
Table 67. Prestige Business Overview
Table 68. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Prestige Opioid-Induced Constipation Product Portfolio
Table 70. Prestige Recent Developments
Table 71. GSK Company Information
Table 72. GSK Business Overview
Table 73. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. GSK Opioid-Induced Constipation Product Portfolio
Table 75. GSK Recent Developments
Table 76. Shionogi Company Information
Table 77. Shionogi Business Overview
Table 78. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Shionogi Opioid-Induced Constipation Product Portfolio
Table 80. Shionogi Recent Developments
Table 81. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 82. Global Opioid-Induced Constipation Sales by Region (2019-2024) & (K Units)
Table 83. Global Opioid-Induced Constipation Sales Market Share by Region (2019-2024)
Table 84. Global Opioid-Induced Constipation Sales by Region (2025-2030) & (K Units)
Table 85. Global Opioid-Induced Constipation Sales Market Share by Region (2025-2030)
Table 86. Global Opioid-Induced Constipation Revenue by Region (2019-2024) & (US$ Million)
Table 87. Global Opioid-Induced Constipation Revenue Market Share by Region (2019-2024)
Table 88. Global Opioid-Induced Constipation Revenue by Region (2025-2030) & (US$ Million)
Table 89. Global Opioid-Induced Constipation Revenue Market Share by Region (2025-2030)
Table 90. North America Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 91. North America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
Table 92. North America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
Table 93. North America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
Table 94. North America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
Table 95. Europe Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 96. Europe Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
Table 97. Europe Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
Table 98. Europe Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
Table 99. Europe Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
Table 100. Asia Pacific Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 101. Asia Pacific Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
Table 102. Asia Pacific Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
Table 103. Asia Pacific Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
Table 104. Asia Pacific Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
Table 105. Latin America Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 106. Latin America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
Table 107. Latin America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
Table 108. Latin America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
Table 109. Latin America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
Table 110. Middle East and Africa Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 111. Middle East and Africa Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
Table 112. Middle East and Africa Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
Table 113. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
Table 114. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
Table 115. Global Opioid-Induced Constipation Sales by Type (2019-2024) & (K Units)
Table 116. Global Opioid-Induced Constipation Sales by Type (2025-2030) & (K Units)
Table 117. Global Opioid-Induced Constipation Sales Market Share by Type (2019-2024)
Table 118. Global Opioid-Induced Constipation Sales Market Share by Type (2025-2030)
Table 119. Global Opioid-Induced Constipation Revenue by Type (2019-2024) & (US$ Million)
Table 120. Global Opioid-Induced Constipation Revenue by Type (2025-2030) & (US$ Million)
Table 121. Global Opioid-Induced Constipation Revenue Market Share by Type (2019-2024)
Table 122. Global Opioid-Induced Constipation Revenue Market Share by Type (2025-2030)
Table 123. Global Opioid-Induced Constipation Price by Type (2019-2024) & (USD/Unit)
Table 124. Global Opioid-Induced Constipation Price by Type (2025-2030) & (USD/Unit)
Table 125. Global Opioid-Induced Constipation Sales by Application (2019-2024) & (K Units)
Table 126. Global Opioid-Induced Constipation Sales by Application (2025-2030) & (K Units)
Table 127. Global Opioid-Induced Constipation Sales Market Share by Application (2019-2024)
Table 128. Global Opioid-Induced Constipation Sales Market Share by Application (2025-2030)
Table 129. Global Opioid-Induced Constipation Revenue by Application (2019-2024) & (US$ Million)
Table 130. Global Opioid-Induced Constipation Revenue by Application (2025-2030) & (US$ Million)
Table 131. Global Opioid-Induced Constipation Revenue Market Share by Application (2019-2024)
Table 132. Global Opioid-Induced Constipation Revenue Market Share by Application (2025-2030)
Table 133. Global Opioid-Induced Constipation Price by Application (2019-2024) & (USD/Unit)
Table 134. Global Opioid-Induced Constipation Price by Application (2025-2030) & (USD/Unit)
Table 135. Key Raw Materials
Table 136. Raw Materials Key Suppliers
Table 137. Opioid-Induced Constipation Distributors List
Table 138. Opioid-Induced Constipation Customers List
Table 139. Opioid-Induced Constipation Industry Trends
Table 140. Opioid-Induced Constipation Industry Drivers
Table 141. Opioid-Induced Constipation Industry Restraints
Table 142. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Opioid-Induced ConstipationProduct Picture
Figure 5. Global Opioid-Induced Constipation Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 6. Global Opioid-Induced Constipation Market Size (2019-2030) & (US$ Million)
Figure 7. Global Opioid-Induced Constipation Sales (2019-2030) & (K Units)
Figure 8. Global Opioid-Induced Constipation Average Price (USD/Unit) & (2019-2030)
Figure 9. Methylnaltrexone Bromide Product Picture
Figure 10. Lubiprostone Product Picture
Figure 11. Naloxegol Product Picture
Figure 12. Others Product Picture
Figure 13. Hospital Product Picture
Figure 14. Pharmacy Product Picture
Figure 15. Other Product Picture
Figure 16. Global Opioid-Induced Constipation Revenue Share by Manufacturers in 2023
Figure 17. Global Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
Figure 18. Global Manufacturers of Opioid-Induced Constipation, Date of Enter into This Industry
Figure 19. Global Top 5 and 10 Opioid-Induced Constipation Players Market Share by Revenue in 2023
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 21. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. Global Opioid-Induced Constipation Sales by Region in 2023
Figure 23. Global Opioid-Induced Constipation Revenue by Region in 2023
Figure 24. North America Opioid-Induced Constipation Market Size by Country in 2023
Figure 25. North America Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
Figure 26. North America Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
Figure 27. U.S. Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Opioid-Induced Constipation Market Size by Country in 2023
Figure 30. Europe Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
Figure 31. Europe Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
Figure 32. Germany Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. France Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. U.K. Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Italy Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Russia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Asia Pacific Opioid-Induced Constipation Market Size by Country in 2023
Figure 38. Asia Pacific Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
Figure 39. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
Figure 40. China Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Japan Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. South Korea Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. India Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Australia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. China Taiwan Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Indonesia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Thailand Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Malaysia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Latin America Opioid-Induced Constipation Market Size by Country in 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings